The State of Alaska Department of Revenue reduced its stake in The Kroger Co. by 32.2% in the fourth quarter, selling 36,775 shares and now holding 77,374 shares valued at $4.83 million. Despite this, other institutional investors increased their positions, maintaining overall institutional ownership at approximately 80.93%. Kroger also reported strong quarterly earnings, beating EPS estimates, providing positive FY2026 guidance, and announcing a quarterly dividend.

Sumitomo Mitsui Trust Group Inc. has reduced its stake in Archer Daniels Midland Company (NYSE:ADM) by 22.4%, selling 341,476 shares and retaining 1,180,368 shares valued at approximately $67.86 million. Analyst ratings for ADM are mixed, with a consensus "Hold" rating and an average price target of $63.86, though recent notes include upgrades and a downgrade. The company beat Q4 EPS estimates and will report Q1 results on May 5, which could act as a near-term catalyst.

Rahul Jalali, CIO of Union Pacific Railroad, emphasizes that scaling AI successfully in an organization hinges on people, culture, and operating models, not just technology. He advocates for platform thinking, fostering trust before accountability, and merging institutional knowledge with new perspectives to drive digital transformation. Jalali implements a "two-in-the-box" model with shared accountability between tech and business leaders to ensure AI adoption addresses business problems and delivers measurable impact.

Robeco Institutional Asset Management B.V. significantly reduced its stake in EPAM Systems, Inc. by 16.0% during the fourth quarter, selling 11,050 shares. Despite this, other institutional investors like MassMutual Private Wealth & Trust FSB and CVA Family Office LLC increased their holdings in the information technology services provider. Analysts have issued varied ratings and price targets for EPAM, with a consensus of "Moderate Buy" and an average target price of $193.56.

Smith & Wesson has announced the release of the Bodyguard 38 2.0 revolver, an enhanced small-frame firearm designed for personal protection. This .38 S&W Special +P double-action only revolver features a lightweight design, ambidextrous controls, and improved sights, with an option for an integrated Crimson Trace red laser. It aims to offer dependable performance and value for everyday carry.

Robeco Institutional Asset Management B.V. increased its stake in Teradata Corporation (NYSE:TDC) by 43.6% in the fourth quarter, purchasing an additional 171,153 shares. This makes their total holdings 564,068 shares, valued at $17.17 million. Other institutional investors also adjusted their positions in Teradata, which reported strong Q4 earnings, beating analyst estimates, and provided positive guidance for Q1 and FY 2026.

Sumitomo Mitsui Trust Group Inc. reduced its stake in Microchip Technology Inc. by 3.7% in the fourth quarter, selling 49,780 shares. This institutional selling, alongside CEO Steve Sanghi's sale of nearly $8 million in shares, comes despite a "Moderate Buy" consensus from analysts and the company beating recent earnings estimates. Microchip Technology continues to show product and commercial growth with new product launches and expanded partnerships.

Generac Holdings Inc. (NYSE: GNRC) announced that it will release its first quarter 2026 financial results before the market opens on Wednesday, April 29, 2026. Following the release, Generac management will host a conference call at 10:00 a.m. EDT to discuss the results, with a webcast available on their Investor Relations website. Generac, founded in 1959, is a global leader in energy technology solutions and power products for residential, commercial, and industrial markets.

Pfizer Inc. is presented as a pharmaceutical giant with a strong economic moat, offering stability to investors seeking defensive plays. The article highlights Pfizer's diversified portfolio, R&D prowess, and global reach in oncology, immunology, rare diseases, and vaccines. It suggests that while pipeline success and patent expirations are critical watchpoints, the company's strategic positioning and financial model make it appealing for long-term growth and income-focused portfolios.

Replimune Group's shares plummeted 75.0% after the FDA rejected its Biologics License Application (BLA) for RP1 plus nivolumab for advanced melanoma, citing trial design concerns despite earlier breakthrough therapy designation. This decision has significantly heightened uncertainty regarding approval timelines and funding, as the company faces substantial losses and limited cash flow. Investors now face a higher risk profile, with opinions on the company's fair value diverging widely.